28389633|t|Leonurine Attenuates Hyperalgesia in Mice with Induced Adenomyosis
28389633|a|BACKGROUND Adenomyosis, defined as the invasion of endometrial glands and stroma into the myometrium, is a common gynecological disorder. In the present study we report on the effect of leonurine on ICR mice with adenomyosis induced by neonatal tamoxifen. MATERIAL AND METHODS After being treated with tamoxifen for 4, 8, and 12 weeks, we assessed body weight and pain modulation in mice in hotplate tests. The mice were divided into 5 groups: a low-dose leonurine treatment group, a high-dose leonurine treatment group, a valproic acid (VPA) treatment group, a vehicle only treatment group, and a blank control group. We evaluated body weight, pain modulation in hotplate tests, and the depth of myometrial infiltration. Immunoreactivity staining of progesterone receptor (PR), nuclear factor-κB phosphorylated-p65 (p-p65), cyclooxygenase-2 (COX-2), and oxytocin receptor (OTR) was evaluated by immunohistochemistry. RESULTS The measurement of the body weight, myometrial infiltration, and pain modulation showed that neonatal tamoxifen treatment led to adenomyosis. Leonurine treatment appeared to decrease hyperalgesia and myometrial infiltration. Immunoreactivity staining showed decreased p-p65, COX-2, and OTR protein expressions. CONCLUSIONS Our results indicate that leonurine attenuates hyperalgesia in mice with induced adenomyosis via down-regulating expressions of p-P65, COX-2, and OTR, and could be beneficial for treating adenomyosis.
28389633	0	9	Leonurine	T109	C0064761
28389633	10	20	Attenuates	T052	C0599946
28389633	21	33	Hyperalgesia	T184	C0020429
28389633	37	41	Mice	T015	C0026809
28389633	47	54	Induced	T169	C0205263
28389633	55	66	Adenomyosis	T047	C0341858
28389633	78	89	Adenomyosis	T047	C0341858
28389633	106	114	invasion	T046	C2699153
28389633	118	136	endometrial glands	T023	C0227848
28389633	141	147	stroma	T023	C0927195
28389633	157	167	myometrium	T023	C0027088
28389633	174	180	common	T081	C0205214
28389633	181	203	gynecological disorder	T047	C0017411
28389633	229	235	report	T170	C0684224
28389633	243	249	effect	T080	C1280500
28389633	253	262	leonurine	T109	C0064761
28389633	266	274	ICR mice	T015	C0025925
28389633	280	291	adenomyosis	T047	C0341858
28389633	292	299	induced	T169	C0205263
28389633	303	311	neonatal	T079	C2939425
28389633	312	321	tamoxifen	T109,T121	C0039286
28389633	356	363	treated	T169	C1522326
28389633	369	378	tamoxifen	T109,T121	C0039286
28389633	406	414	assessed	T052	C1516048
28389633	415	426	body weight	T032	C0005910
28389633	431	435	pain	T184	C0030193
28389633	450	454	mice	T015	C0026809
28389633	458	466	hotplate	T074	C0182315
28389633	467	472	tests	T059	C0022885
28389633	478	482	mice	T015	C0026809
28389633	488	495	divided	T169	C0332849
28389633	503	509	groups	T078	C0441833
28389633	513	521	low-dose	T081	C0445550
28389633	522	531	leonurine	T109	C0064761
28389633	532	541	treatment	T061	C0087111
28389633	542	547	group	T078	C0441833
28389633	551	560	high-dose	T081	C0444956
28389633	561	570	leonurine	T109	C0064761
28389633	571	580	treatment	T061	C0087111
28389633	581	586	group	T078	C0441833
28389633	590	603	valproic acid	T109,T121	C0042291
28389633	605	608	VPA	T109,T121	C0042291
28389633	610	619	treatment	T061	C0087111
28389633	620	625	group	T078	C0441833
28389633	629	636	vehicle	T122	C0042444
28389633	637	641	only	T081	C0205171
28389633	642	651	treatment	T061	C0087111
28389633	652	657	group	T078	C0441833
28389633	665	670	blank	T033	C0750479
28389633	671	684	control group	T096	C0009932
28389633	689	698	evaluated	T058	C0220825
28389633	699	710	body weight	T032	C0005910
28389633	731	739	hotplate	T074	C0182315
28389633	740	745	tests	T059	C0022885
28389633	755	760	depth	T082	C0205125
28389633	764	774	myometrial	T029	C0521387
28389633	775	787	infiltration	T046	C0332448
28389633	789	805	Immunoreactivity	T044	C0597879
28389633	806	814	staining	T059	C0487602
28389633	818	839	progesterone receptor	T116,T192	C0034833
28389633	841	843	PR	T116,T192	C0034833
28389633	846	882	nuclear factor-κB phosphorylated-p65	T116,T123	C1567061
28389633	884	889	p-p65	T116,T123	C1567061
28389633	892	908	cyclooxygenase-2	T116,T126	C1447194
28389633	910	915	COX-2	T116,T126	C1447194
28389633	922	939	oxytocin receptor	T116,T192	C3849099
28389633	941	944	OTR	T116,T192	C3849099
28389633	950	959	evaluated	T058	C0220825
28389633	963	983	immunohistochemistry	T060	C0021044
28389633	997	1008	measurement	T169	C0242485
28389633	1016	1027	body weight	T032	C0005910
28389633	1029	1039	myometrial	T029	C0521387
28389633	1040	1052	infiltration	T046	C0332448
28389633	1086	1094	neonatal	T079	C2939425
28389633	1095	1104	tamoxifen	T109,T121	C0039286
28389633	1105	1114	treatment	T061	C0087111
28389633	1122	1133	adenomyosis	T047	C0341858
28389633	1135	1144	Leonurine	T109	C0064761
28389633	1145	1154	treatment	T061	C0087111
28389633	1167	1175	decrease	T081	C0547047
28389633	1176	1188	hyperalgesia	T184	C0020429
28389633	1193	1203	myometrial	T029	C0521387
28389633	1204	1216	infiltration	T046	C0332448
28389633	1218	1234	Immunoreactivity	T044	C0597879
28389633	1235	1243	staining	T059	C0487602
28389633	1251	1260	decreased	T081	C0205216
28389633	1261	1266	p-p65	T116,T123	C1567061
28389633	1268	1273	COX-2	T116,T126	C1447194
28389633	1279	1282	OTR	T116,T192	C3849099
28389633	1283	1302	protein expressions	T045	C1171362
28389633	1342	1351	leonurine	T109	C0064761
28389633	1352	1362	attenuates	T052	C0599946
28389633	1363	1375	hyperalgesia	T184	C0020429
28389633	1379	1383	mice	T015	C0026809
28389633	1389	1396	induced	T169	C0205263
28389633	1397	1408	adenomyosis	T047	C0341858
28389633	1413	1428	down-regulating	T044	C0013081
28389633	1429	1440	expressions	T045	C1171362
28389633	1444	1449	p-P65	T116,T123	C1567061
28389633	1451	1456	COX-2	T116,T126	C1447194
28389633	1462	1465	OTR	T116,T192	C3849099
28389633	1495	1503	treating	T169	C1522326
28389633	1504	1515	adenomyosis	T047	C0341858